Misoprostol Shortage: What Providers and Prescribers Need to Know in 2026

Misoprostol has been on pharmacists' shelves since 1988, but its availability landscape has changed substantially. For clinicians who routinely prescribe misoprostol — whether for NSAID ulcer prophylaxis, obstetric indications, or reproductive health — understanding the 2026 supply environment is essential for protecting continuity of care.

Current Supply Status (2026 Update)

Misoprostol is not on the FDA's drug shortage list as of early 2026. ASHP confirms that all marketed presentations remain commercially available:

Cytotec (Pfizer) — 100 mcg and 200 mcg tablets in bottle and unit-dose blister packs

Generic misoprostol (Greenstone/Viatris) — 100 mcg and 200 mcg tablets available

However, Lupin's discontinuation of their generic version has narrowed the supplier base. This increases systemic risk: any manufacturing disruption at Pfizer or Viatris could create a true shortage quickly. Clinicians who use misoprostol heavily should be aware of this fragility.

The Legal Landscape: What Has Changed Since 2022

The post-Dobbs regulatory environment has created a fragmented and rapidly evolving landscape for misoprostol prescribing. Key developments providers must track:

State-level reclassification attempts. Louisiana passed legislation attempting to classify mifepristone and misoprostol as controlled dangerous substances. Several other states have similar legislation under consideration. These laws do not change federal scheduling (misoprostol remains unscheduled federally), but they create legal exposure for prescribers and dispensers in those states.

REMS requirements for mifepristone. While misoprostol itself does not have a REMS program, the combination regimen with mifepristone is subject to mifepristone's REMS (Risk Evaluation and Mitigation Strategy), which requires prescriber certification.

Conscience clause variations. Pharmacist conscience clauses in some states allow refusal to dispense. Providers should be aware that even a legally valid prescription may be refused at certain retail pharmacies in these states.

FDA telehealth dispensing rules. FDA regulations allow certified healthcare professionals to prescribe mifepristone and misoprostol via telehealth and certified pharmacies to dispense by mail. State laws may override this in certain jurisdictions.

How Access Disparities Affect Your Patients

Patients in rural areas, low-resource settings, or restrictive states face the greatest barriers. But even urban patients report that some chain pharmacies don't stock misoprostol or keep only minimal quantities on hand. Patients in these situations may delay care, seek alternatives, or go without — with clinical consequences that providers need to anticipate.

For NSAID-related prescribing, consider proactively counseling patients about which local pharmacies reliably stock misoprostol — or switch to a PPI, which is often better tolerated and more universally accessible. For obstetric and reproductive health uses, having clear pharmacy referral protocols in place is increasingly essential practice management.

Clinical Protocols: Alternatives When Misoprostol Is Unavailable

Providers should have pre-built contingency protocols. Evidence-based alternatives by indication:

NSAID ulcer prophylaxis: Switch to a PPI (omeprazole, pantoprazole, lansoprazole) — generally preferred for tolerability and once-daily dosing. COX-2 selective NSAIDs (celecoxib) may reduce or eliminate the need for mucosal protection.

Medical abortion: WHO and ACOG recommend misoprostol-only (800 mcg sublingually/buccally/vaginally, repeated every 3 hours up to 3 doses) when mifepristone is unavailable. Surgical aspiration remains a safe alternative.

Labor induction: Dinoprostone (Cervidil, Prepidil) is FDA-approved for cervical ripening and is an established alternative. Oxytocin IV augmentation with mechanical dilation (Foley balloon, osmotic dilators) is another option.

Postpartum hemorrhage: Oxytocin remains the first-line uterotonic agent where IV access is available. Carboprost (Hemabate) is another option. WHO recommends misoprostol 600-1000 mcg as the preferred uterotonic when oxytocin is unavailable.

How to Help Your Patients Find Misoprostol

Providers can refer patients to medfinder for providers — a service that contacts pharmacies near the patient to identify which ones have their specific medication in stock. For practices that frequently prescribe misoprostol, having this resource in your care coordination toolkit can reduce appointment delays and improve patient outcomes.

For more detail, see our guide on how to help your patients find misoprostol in stock, including communication scripts, pharmacy referral workflows, and documentation considerations.